Roche "Disappointed" By ASCO Focus, Progressing CEA-CD3 Bispecific

 
• By Sten Stovall

Roche CEO Severin Schwan says analysts at ASCO missed a key APHINITY message on Herceptin follow-on Perjeta, and that the Swiss group will swiftly progress its CEA-CD3 bispecific to pivotal studies based on data presented there.

Schwan_Severin_1200x675
Severin Schwan "Disappointed" By ASCO APHINITY Reactions • Source: Roche AG

More from Business

More from Scrip